宫颈癌患者盆腔和/或腹主动脉旁淋巴结转移的预后价值及新版FIGO分期(IIIC期)的影响
基于荷兰癌症登记处的全国性回顾性队列研究,纳入2005至2018年新诊断的6082例IB-IVA期宫颈癌患者,评估盆腔和/或腹主动脉旁淋巴结转移的预后价值。结果显示,2009 FIGO IB-IIB期伴淋巴结转移者总生存显著低于无转移者,而IIIA-IVA期淋巴结转移对生存无显著影响;2018 FIGO IIIC期3年、5年和15年总生存分别为72%、65%和59%。
要点
- 2009 FIGO IB-IIB期宫颈癌伴盆腔和/或腹主动脉旁淋巴结转移者总生存显著低于无转移者。
- 2009 FIGO IIIA-IVA期宫颈癌淋巴结转移与无转移者总生存无显著差异(p=0.064)。
- 2018 FIGO IIIC期影像学诊断(IIICr)者生存显著低于病理学诊断(IIICp)者(p<0.001)。
核心结论
- 2009 FIGO IB-IIB期宫颈癌伴盆腔和/或腹主动脉旁淋巴结转移者较无转移者生存显著受损。
- 2009 FIGO IIIA-IVA期宫颈癌患者生存不受淋巴结转移影响。
研究设计与样本
- 全国性回顾性队列研究,数据来自荷兰癌症登记处,纳入2005至2018年新诊断的2009 FIGO IB-IVA期宫颈癌患者,共6082例。
- 采用Kaplan-Meier法估计3年、5年和15年总生存率。
主要发现
- 6082例患者中1740例(29%)存在盆腔和/或腹主动脉旁淋巴结转移。
- 2009 FIGO IB-IB1-IIA-IIA1期伴淋巴结转移者5年总生存为77%,无转移者为92%(p<0.001)。
- 2009 FIGO IB2-IIA2-IIB期伴淋巴结转移者5年总生存为67%,无转移者为74%(p=0.009)。
- 2009 FIGO IIIA-IIIB-IVA期伴与不伴淋巴结转移者生存率无显著差异(p=0.064)。
- 2018 FIGO IIIC期3年、5年和15年总生存分别为72%、65%和59%。
关键数值与推荐
- 2009 FIGO IB-IB1-IIA-IIA1期伴淋巴结转移者5年总生存77% vs 无转移者92%(p<0.001)。
- 2009 FIGO IB2-IIA2-IIB期伴淋巴结转移者5年总生存67% vs 无转移者74%(p=0.009)。
- 2009 FIGO IIIA-IIIB-IVA期伴与不伴淋巴结转移者生存率无显著差异(p=0.064)。
- 2018 FIGO IIIC期3年、5年和15年总生存分别为72%、65%和59%。
- IIICr期生存显著低于IIICp期(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: One of the major changes in the revised (2018) FIGO-staging system is the addition of stage IIIC to the previously used 2009 system. We evaluated the prognostic value of positive pelvic and/or para-aortic lymph nodes in patients with cervical cancer. METHODS: A nationwide retrospective cohort study was performed by analyzing data from the Netherlands Cancer Registry. All patients newly diagnosed with stage IB-IVA between 2005 and 2018 were identified. Three-year, 5-year and 15-year overall survival (OS) rates were estimated with the Kaplan-Meier method. RESULTS: Of the included 6082 patients, 1740 patients (29%) had pelvic and/or para-aortic lymph node metastases. For patients with FIGO 2009 stage IB-IB1-IIA-IIA1 and stage IB2-IIA2-IIB with pelvic and/or para-aortic lymph node metastases the OS was significantly different (p < 0.001 and p = 0.009), with a 5-year OS of 77% and 67%, compared with 92% and 74% for women without lymph node metastases. For FIGO 2009 stage IIIA-IIIB-IVA with and without lymph node metastases, survival rates are not significantly different (p = 0.064). For FIGO 2018 stage IIIC the 3y-OS, 5y-OS and 15-year OS are 72%, 65% and 59% respectively. Survival rates of IIIC diagnosed based on imaging (IIICr) are significantly impaired compared to stage IIIC diagnosed based on pathology (IIICp) (p < 0.001). CONCLUSION: Patients with FIGO 2009 stage IB-IIB cervical cancer with pelvic and/or para-aortic lymph node metastases have significantly impaired survival compared to patients without metastases. Survival rates of patients with FIGO 2009 stage IIIA-IVA are not affected by lymph node metastases.
引用
- van Kol KGG, Ebisch RMF, van der Aa M, et al. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC). Gynecol Oncol. 2023. PMID: 36804623. doi:10.1016/j.ygyno.2023.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。